中国女性乳腺癌筛查与早诊早治指南(2021,北京)

China guideline for the screening and early detection of female breast cancer(2021,Beijing)

乳腺癌是中国女性最常见的恶性肿瘤,发病率位居中国女性恶性肿瘤首位。国家癌症中心受国家卫生健康委员会疾病预防控制局委托,根据《世界卫生组织指南制定手册》制定女性乳腺癌筛查与早诊早治指南。制作系统评价流程参考Cochrane协作网的方法,证据质量与推荐强度的分级采用推荐意见分级的评估、制定及评价方法,并根据国际实践指南报告规范条目进行报告。在系统评价结果的基础上,结合中国国情,综合考虑了证据的利弊、证据的质量、筛查经济成本、多学科临床调查对象的反馈和面对面的专家共识意见,针对乳腺癌筛查与早诊早治中适宜人群、技术流程等进行循证推荐,旨在规范女性乳腺癌筛查与早诊早治实践,提升中国女性乳腺癌防控效果。

Breast cancer is the commonest malignant tumor among Chinese females,ranking first in terms of incidence of female cancers.Commissioned by the Disease Prevention and Control Bureau of National Health Commission of the People′s Republic of China,the National Cancer Center formulated the Guideline for Screening and Early Diagnosis and Treatment of Female Breast Cancer in China according to WHO Handbook for Guideline Development.The methods on Cochrane China were referred to for the formulation of the system evaluation procedures.The GRADE methods for assessment,formulation and evaluation were adopted for the classification of evidence quality and recommendation strength,and the items were reported according to Reporting Items for Practice Guidelines in Healthcare.Based on the results of evaluation,the guideline gives evidence-based recommendations for the appropriate population and technical procedures for breast cancer screening and early diagnosis and treatment after comprehensive consideration of China′s national conditions,the advantages and disadvantages of the evidence,the quality of the evidence,the economic cost of screening,the feedback of multidisciplinary clinical research respondents,and in-person expert consensus.It is aimed at regulating the practices of female breast cancer screening and early diagnosis and treatment and enhancing the effectiveness of the prevention and control of female breast cancer in China.